Edesa Biotech (EDSA)

• Market cap: $65.4M
• 1 day: 6.83%
• 5 days: 30.09%
• 1 month: -18.33%
• 3 months: -4.42%
• 6 months: 400%
• Year to date: 390%
• 1 year: 260.29%
• 5 years: -81.18%
• 10 years: -99.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Employees: 17